| Metric | Value ($ M) | Q1 FY26 |
|---|---|---|
| Revenue | 24.1K | 9.9% |
| Total Income | 24.1K | 9.9% |
| Expenditure | 18.1K | 118.7% |
| PBT | 6.0K | 56.1% |
| Net Profit | 5.2K | 52.4% |
| OPM | — | |
| NPM | 21.76% | 28.48pp |
| EPS | 2.17 | 52.5% |
Johnson & Johnson Reports Q1 2026 Sales Growth of 9.9% to $24.1B, EPS $2.14
14 Apr 2026 · 14 Apr, 5:11 pm
Summary
Johnson & Johnson reported a strong start to 2026 with first-quarter sales increasing by 9.9% to $24.1 billion. Net earnings decreased by 52.4% to $5.235 billion, resulting in an EPS of $2.14. The company raised its 2026 guidance, projecting reported sales of $100.8 billion and adjusted EPS of $11.55.
Key Highlights
- 1
Revenue: $24.1B (up 9.9% YoY)
- 2
Net Income: $5.235B (down 52.4% YoY)
- 3
EPS: $2.14
- 4
Adjusted EPS: $2.70
Management Comments
Joaquin Duato
Johnson & Johnson had a strong start to 2026 and is delivering on its promise for a year of accelerated growth and impact. The depth and strength of our portfolio and pipeline is unrivaled and our relentless focus on innovation delivered multiple game-changing approvals this quarter, including ICOTYDE in the U.S. for moderate to severe plaque psoriasis and VARIPULSE Pro in Europe. These advancements have the potential to transform patient outcomes and create sustainable, long-term value for shareholders.
Informational and educational content only. Not investment advice.